The overall goal of this clinical trial is to study how prehospital transfused dry plasma affect outcomes in terms of mortality as well as complications and coagulation status of patients in or about to develop bleeding shock.
Researchers will compare dry plasma to standard care to see if dry plasma improves survival compared to crystalloid fluid in prehospital patients with heavy bleeding.
Patients with clinical signs of bleeding which also triggers resuscitation with crisalloids acording to standard care protocol.
Patients < 18 years of age.
Patients who lack clinical signs of major bleeding.
Parallel
Dry plasma
Biological/VaccinePatient that fulfil the inclusion criteria for this study and are randomized for active treatment will get dry plasma as intervention.
Mortality
Overall mortality at 24 hours after hospital admission. Will include patients dead at scene or during transportation.
Mortality for patients with bleeding > 500 mL (milliliter)
Specific mortality for patients with a bleeding \> 500mL at 24 hours after hospital admission. Will include patients dead at scene or during transport.
Shock Index
Shock Index \> 1.3.
Coagulopathy overall
PK/INR \> 1.2 and/or Platelet count \< 150 x 109/L and/or APTT \> 34 s or each valuable alone. INR= international normalized ratio PK= prothrombin complex. APTT= activated partial thromboplastin time.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
